Scholarlink

Background <p>Neoadjuvant chemo-immunotherapy has shown promise in improving survival outcomes for non-small cell lung cancer (NSCLC) patients, with pathologic response serving as a critical predictor of long-term outcomes. However, manual assessment of pathologic response is labor-intensive and subject to inter-observer variability. This study aimed to develop an automated AI-based solution to address these limitations.</p> Methods <p>We developed an AI-powered patch-based image analysis model to quantify residual viable tumor (RVT) in hematoxylin and eosin (H&amp;E)-stained whole slide images. The model was evaluated on resected specimens from 47 NSCLC patients treated with neoadjuvant chemo-immunotherapy. The AI-derived estimates of RVT were compared with visual assessments by a board-certified pathologist. Statistical analysis included Pearson’s correlation for continuous tumor estimation and Cohen’s Kappa for concordance in major pathologic response (MPR) and pathologic complete response (pCR) classification.</p> Results <p>The AI model demonstrated a strong correlation with the pathologist’s continuous estimation of RVT (<i>r</i> = 0.77, <i>p</i> &lt; 0.001, confidence interval [CI]: 0.73–0.81). In the assessment of clinical endpoints, the model achieved an 89.36% concordance rate for MPR (Kappa = 0.79, <i>p</i> &lt; 0.001, CI: 0.61–0.96) and 89.36% concordance rate for pCR (Kappa = 0.56, <i>p</i> &lt; 0.001, CI: 0.24–0.89) when compared with the board-certified pathologist.</p> Conclusions <p>Our AI-powered model demonstrates potential as a decision-support tool for pathologic response assessments in NSCLC patients treated with neoadjuvant chemo-immunotherapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Diagnostic accuracy of an AI-based pathologic response assessment in locally advanced non-small cell lung cancer after neoadjuvant chemo-immunotherapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月20日

查看全文
  • Ki-Chang Lee,
  • Haenara Shin,
  • Jungyoon Ohn,
  • Ji Hyeon Park,
  • Samina Park,
  • In Kyu Park,
  • Chang Hyun Kang,
  • Young Tae Kim,
  • Hongyoon Choi,
  • Jaemoon Koh,
  • Kwon Joong Na

摘要

Background

Neoadjuvant chemo-immunotherapy has shown promise in improving survival outcomes for non-small cell lung cancer (NSCLC) patients, with pathologic response serving as a critical predictor of long-term outcomes. However, manual assessment of pathologic response is labor-intensive and subject to inter-observer variability. This study aimed to develop an automated AI-based solution to address these limitations.

Methods

We developed an AI-powered patch-based image analysis model to quantify residual viable tumor (RVT) in hematoxylin and eosin (H&E)-stained whole slide images. The model was evaluated on resected specimens from 47 NSCLC patients treated with neoadjuvant chemo-immunotherapy. The AI-derived estimates of RVT were compared with visual assessments by a board-certified pathologist. Statistical analysis included Pearson’s correlation for continuous tumor estimation and Cohen’s Kappa for concordance in major pathologic response (MPR) and pathologic complete response (pCR) classification.

Results

The AI model demonstrated a strong correlation with the pathologist’s continuous estimation of RVT (r = 0.77, p < 0.001, confidence interval [CI]: 0.73–0.81). In the assessment of clinical endpoints, the model achieved an 89.36% concordance rate for MPR (Kappa = 0.79, p < 0.001, CI: 0.61–0.96) and 89.36% concordance rate for pCR (Kappa = 0.56, p < 0.001, CI: 0.24–0.89) when compared with the board-certified pathologist.

Conclusions

Our AI-powered model demonstrates potential as a decision-support tool for pathologic response assessments in NSCLC patients treated with neoadjuvant chemo-immunotherapy.